Why the Bionomics (ASX:BNO) share price is climbing today

The Bionomics Ltd (ASX: BNO) share price is climbing higher today on news it has received commitments for a capital raise.

| More on:
Giant magnet attracting banknotes to symbolise a capital raising.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Bionomics Ltd (ASX: BNO) share price continues to climb today after the company announced it had received commitments for a placement.

At the time of writing, shares in the clinical-stage biopharmaceutical company are up 2.2% to 22.5 cents. Today's movement follows major gains for the Bionomics share price recently, up 48% over the past week.

What's moving the Bionomics share price?

Bionomics advised that it has entered agreements for a placement with several North American and European institutional and sophisticated investors to raise almost $16 million.

Under listing rule 7.1, the company will use its 15% placement capacity to issue 110,287,132 ordinary shares to eligible investors. Each share price will be offered at 14.5 cents, reflecting a 20% discount on the 30-day volume-weighted average recorded on 5 February. Notably, the new parcel of shares is trading at a 55% discount based on the current Bionomics share price.

The company expects the placement to be completed before 26 February.

Once the capital raise is wrapped up, Bionomics will launch an entitlement offer to its existing shareholders. The share purchase plan will offer the same price of 14.5 cents apiece. Bionomics will release further details to the ASX market in due course.

In addition, Apeiron Investment Group will help fund Bionomics' BNC210 Phase 2b Clinical trials to treat post-traumatic stress disorder (PTSD). This was conducted with Apeiron underwriting a further raising of $15 million at a minimum price of 6 cents per share.

Management commentary

Bionomics executive chair Dr Errol De Souza welcomed the progress, saying:

We were pleased that a number of well-known specialist life sciences investment funds participated adding to a very strong shareholder base, which includes Apeiron Investments, Biotech Value Fund, Merck, Peter Thiel and Mike Novagratz.

We remain on track to the completion of our ongoing 7-day dosing pharmacokinetic study of our novel BNC210 tablet formulation in 1Q CY2021 and starting the Phase 2b PTSD trial in mid-2021.

Apeiron founder Christian Angermayer added:

We are pleased to support Bionomics both as an underwriter in this placement and as a long-term shareholder of the company. We look forward to participating in the entitlement offer alongside other investors.

PTSD and other mental health disorders are enormous burdens for those that live with them. Bionomics' lead drug BNC210 has already received fast track designation from the FDA and I am confident of the strong potential of the upcoming Phase 2b PTSD trial to drive value for both patients and shareholders.

Foolish takeaway

The Bionomics share price has accelerated over the past 12 months, gaining more than 228%. The company's shares hit a low of 3 cents in March, before moving on an upwards trajectory.

At the current share price, Bionomics commands a market capitalisation of $165 million.

Should you invest $1,000 in Openpay Group right now?

Before you buy Openpay Group shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Openpay Group wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man and woman sit at a desk staring intently at a laptop screen with papers next to them.
Opinions

Where I'd invest $5,000 in ASX 300 shares right now

These stocks look like excellent investments today.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Goldman Sachs says these ASX 200 stocks are strong buys

The broker is feeling very bullish about these stocks. But why?

Read more »

Business woman watching stocks and trends while thinking
Share Market News

5 things to watch on the ASX 200 on Wednesday

Here's what to expect on the local market today.

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors this Tuesday.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why HMC Capital, Platinum, Sigma, and Skycity shares are dropping today

These shares are having a tough session on Tuesday. But why?

Read more »

A close-up photo of a ballot box with an Australian flag in front of it and a gentleman's hands placing his vote in the 2022 election inside the box
Share Market News

How these ASX 200 stocks are primed to gain from Labor's resounding Federal election win

With the Federal election in the rear-view, which ASX 200 stocks should I buy now?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Dimerix, Evolution Mining, Inghams, and NextDC shares are charging higher today

These shares are rising when many are falling today. But why?

Read more »

Smiling young woman eating chocolate outdoors.
Share Market News

The See's Candies playbook for ASX investors

Two ASX businesses that remind me of Buffett’s sweetest investment.

Read more »